Compare Recursion Pharmaceuticals Inc (RXRX) vs Upwork Inc (UPWK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Recursion Pharmaceuticals Inc vs Upwork Inc — how do they compare? Recursion Pharmaceuticals Inc trades at $4 (market cap $2.14B), while Upwork Inc trades at $8.57 (market cap $1.07B). The key difference: Recursion Pharmaceuticals Inc is far larger — about 2× Upwork Inc's market cap, and Recursion Pharmaceuticals Inc is trading nearer its 52-week high, Upwork Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Recursion Pharmaceuticals Inc for 22 Days and Upwork Inc for 38 Days on average.
| RXRX | UPWK | |
|---|---|---|
Market Cap | $2.14B | $1.07B |
Volume | 30,789,535 | 2,574,130 |
Sector | Health | Industrials |
52-Week High | $6.79 | $22.11 |
52-Week Low | $2.84 | $7.84 |
Typical Hold Time | 22 Days | 38 Days |
Enterprise Value | $1.66B | $833.01M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RXRX trades at $4.27, down 7.78% today, with technical indicators showing a bullish trend despite recent weakness. The company reported Q2 2026 earnings miss after two consecutive beats, with revenue declining to $54 million in 2026 from $74 million in 2025. While maintaining a negative net income margin of -961.97%, RXRX continues to expand its AI-powered drug discovery platform through strategic partnerships with Tempus and Roche.
The stock presents high-risk growth potential with strong analyst support (40% buy rating) but faces significant execution challenges. Investment appeal hinges on successful pipeline development and commercialization of AI drug discovery technology, though persistent losses and declining revenue create substantial downside risk for shareholders.
Upwork (UPWK) trades at $8.40, up 0.48% on the day, with a bearish technical signal and neutral oscillators. The company reported Q2 2026 EPS of $0.41, beating expectations, but revenue growth has slowed, with 2025 revenue at $787.78 million. Valuation metrics appear attractive with a P/E of 10.77 and P/S of 1.45. Recent news highlights insider sales and a securities fraud investigation, while Bank of America acquired a significant stake.
The outlook is mixed: low valuation and strong profitability margins offer upside, but AI competition and recent insider selling pose risks. Analyst consensus is a Buy with a $9.64 price target, implying potential appreciation, though sentiment is cautious due to growth concerns and legal scrutiny.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →About Upwork Inc
Upwork Inc is a United States-based company that operates an online marketplace that enables businesses to find and work with highly-skilled independent professionals. The develops platform for hiring and freelancing purposes. Its products offering include Upwork Basic, Upwork Plus, Upwork Business, Upwork Enterprise, and Upwork Payroll. The business generates revenue from Talent and Clients across the USA, India, the Philippines and the rest of the world. Substantial income is derived from providing services to Clients.
Read more on UPWK →
